Overview

Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Status:
Withdrawn

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine whether the administration of bevacizumab and gemcitabine given by IV infusion can prolong survival, delay tumor growth, and/or shrink tumors in patients with ovarian cancer, primary peritoneal, or fallopian tube cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Emory University

Collaborator:

Genentech, Inc.

Treatments:

Bevacizumab
Gemcitabine